Jazz Pharmaceuticals: Cantor’s Irina Rivkind Revisits Xyrem Litigation


Cantor analyst Irina Rivkind was out today pounding the table on Jazz Pharmaceuticals (NASDAQ:JAZZ) Monday, reiterating a Hold rating and a price target of $195.

Rivkind wrote, “We think a Xyrem settlement could occur pre-trial since the company’s best case settlement relies on a single patent of questionable defensive value: Management noted that “the whole ballgame” is focused on the expected 2H:15 trial with Roxane in the District Court of New Jersey, where the company will be litigating its Orange Book-listed formulation/method-of-use patents (we estimate seven formulation/method patents and 85 claims to be litigated).”

Furthermore, “We combed through the Xyrem patent estate and think the success of Jazz’s generic defense will essentially hang on a single method patent that can be carved out, in our view (8,772,306 which expires in 2033 and has 34 claims). We note the remaining patents expire in the 2019-2020 time frame, which may not provide adequate time to switch patients to JZP-386 or a less optimal brand extension (and wins on any of these claims may not remove the overhang on the stock). We therefore think that a pre-trial settlement on the ‘306 patent represents the best-case/upside scenario for Jazz.”

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts